Aspen Neuroscience Completes First ASPIRO Phase 1/2a Dosing for Parkinson's

Aspen Neuroscience has announced the successful dosing of the initial cohort of patients in their ASPIRO study, a significant milestone for the company. Surgical safety data from this first group has been accepted for late breaking presentations at the MDS International Congress of Parkinson's Disease and Movement Disorders, scheduled to take place in Philadelphia from September 27 to October 1.

Edward Wirth III, MD, PhD, Chief Medical Officer of Aspen Neuroscience, expressed pride in the acceptance of their surgical safety data by the Society. He highlighted the company's rapid progress since the launch of the study earlier in the year and emphasized the importance of sharing their findings with experts in movement disorders.

The ASPIRO study, formally known as the Autologous-derived Study of a Parkinson's Investigational Regenerative therapy in an Open-label trial, is a Phase 1/2a clinical trial. This trial aims to evaluate the safety, tolerability, and potential efficacy of ANPD001 in patients suffering from moderate to severe Parkinson's disease. The primary endpoint of the study focuses on the safety and tolerability of ANPD001.

A notable aspect of the ASPIRO study is its cell transplantation approach, which was developed by lead neurosurgeon Paul Larson, MD, FAANS. Dr. Larson is a professor of neurosurgery at the University of Arizona College of Medicine – Tucson and a neurosurgeon at Banner University Medical Center in Tucson. He is renowned for his expertise in MRI-guided stereotactic neurosurgery.

In addition to presenting multiple scientific findings, Aspen Neuroscience will also participate in the congress as a Bronze Level sponsor. The company will have a presence at booth #1003, where they will showcase their latest developments and company highlights.

Aspen Neuroscience, Inc. is based in San Diego and focuses on autologous regenerative medicine. The company's patient-derived iPSC (induced pluripotent stem cell) platform is used to develop personalized therapies. This approach is particularly valuable for addressing diseases with high unmet medical needs, starting with autologous neuron replacement for Parkinson's disease.

Aspen Neuroscience integrates cell biology with cutting-edge machine learning and genomic techniques to explore patient-specific, restorative cell treatments. The company is dedicated to maintaining high standards of quality through its best-in-class platform, which includes in-house bioinformatics, manufacturing, and quality control.

The upcoming presentations at the MDS International Congress of Parkinson's Disease and Movement Disorders will be an important opportunity for Aspen Neuroscience to share their latest surgical safety data and engage with the broader scientific community on advancements in the treatment of Parkinson's disease.